Skip to main content

Table 2 Baseline patient characteristics according to total patients, NLR, dNLR, PLR and LMR level

From: Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model

Characteristics   Total patients (n = 389) Patients grouped by NLR level (n = 389) P * Patients grouped by dNLR level (n = 389) P * Patients grouped by PLR level (n = 389) P * Patients grouped by LMR level (n = 389) P *
NLR < 2.36 (n = 132) NLR ≥ 2.36 (n = 257) dNLR < 1.85 (n = 151) dNLR ≥ 1.85 (n = 238) PLR < 132 (n = 165) PLR ≥ 132 (n = 224) LMR < 4.95 (n = 241) LMR ≥ 4.95 (n = 148)
Sex Female 107 (27.5%) 37 (28.0%) 70 (27.2%) 0.868 41 (27.2%) 66 (27.7%) 0.901 54 (32.7%) 53 (23.7%) 0.048 59 (24.5%) 48 (32.4%) 0.088
Male 282 (72.5%) 95 (72.0%) 187 (72.8%) 110 (72.8%) 172 (72.3%) 111 (67.3%) 171 (76.3%) 182 (75.5%) 100 (67.6%)
Age (years) <65 185 (47.6%) 74 (56.1%) 111 (43.2%) 0.016 83 (55.0%) 102 (42.9%) 0.020 87 (52.7%) 98 (43.8%) 0.080 98 (40.7%) 87 (58.8%) 0.001
≥65 204 (52.4%) 58 (43.9%) 146 (56.8%) 68 (45.0%) 136 (57.1%) 78 (47.3%) 126 (56.2%) 143 (59.3%) 61 (41.2%)
Alcohol Yes 73 (18.8%) 31 (23.5%) 42 (16.3%) 0.088 32 (21.2%) 41 (17.2%) 0.329 36 (21.8%) 37 (16.5%) 0.186 44 (18.3%) 29 (19.6%) 0.743
No 316 (81.2%) 101 (76.5%) 215 (83.7%) 119 (78.8%) 197 (82.8%) 129 (78.2%) 187 (83.5%) 197 (81.7%) 119 (80.4%)
Tobacco Yes 72 (18.5%) 29 (22.0%) 43 (16.7%) 0.208 30 (19.9%) 42 (17.6%) 0.583 37 (22.4%) 35 (15.6%) 0.088 46 (19.1%) 26 (17.6%) 0.708
No 317 (81.5%) 103 (78.0%) 214 (83.3%) 121 (80.1%) 196 (82.4%) 128 (77.6%) 189 (84.4%) 195 (80.9%) 122 (82.4%)
Family history Yes 15 (3.9%) 4 (3.0%) 11 (4.3%) 0.544 5 (3.3%) 10 (4.2%) 0.657 9 (5.5%) 6 (2.7%) 0.160 6 (2.5%) 9 (6.1%) 0.100
No 374 (96.1%) 128 (97.0%) 246 (95.7%) 146 (96.7%) 228 (95.8%) 156 (94.5%) 218 (97.3%) 235 (97.5%) 139 (93.9%)
Histological type papillary 19 (4.9%) 8 (6.1%) 11 (4.3%) 0.543 10 (6.7%) 9 (3.8%) 0.424 15 (9.1%) 4 (1.8%) 0.009 9 (3.7%) 10 (6.8%) 0.260
tubular 81 (20.8%) 26 (19.7%) 55 (21.4%) 32 (21.1%) 49 (20.6%) 30 (18.2%) 51 (22.8%) 45 (18.7%) 36 (24.3%)
   poorly differentiated 203 (52.2%) 66 (50.0%) 137 (53.3%) 74 (49.0%) 129 (54.2%) 79 (47.9%) 124 (55.4%) 135 (56.0%) 68 (45.9%)
  mucinous 57 (14.7%) 24 (18.1%) 33 (12.8%) 26 (17.2%) 31 (13.0%) 28 (16.9%) 29 (12.9%) 33 (13.7%) 24 (16.2%)
   signetring cell 29 (7.4%) 8 (6.1%) 21 (8.2%) 9 (6.0%) 20 (8.4%) 13 (7.9%) 16 (7.1%) 18 (7.5%) 11 (7.4%)
Tumor grade G1-G2 214 (55.0%) 68 (51.5%) 146 (56.8%) 0.320 78 (51.7%) 136 (58.0%) 0.289 85 (51.5%) 129 (57.6%) 0.234 133 (55.2%) 81 (54.7%) 0.930
G3-G4 175 (45.0%) 64 (48.5%) 111 (43.2%) 73 (48.3%) 102 (42.0%) 80 (48.5%) 95 (42.4%) 108 (44.8%) 67 (45.3%)
Tumor stage I-II 159 (40.9%) 95 (72.0%) 64 (24.9%) 0.000 78 (51.7%) 81 (34.0%) 0.001 83 (50.3%) 76 (33.9%) 0.001 72 (29.9%) 87 (58.8%) 0.000
III-IV 230 (59.1%) 37 (28.0%) 193 (75.1%) 73 (48.3%) 157 (66.0%) 82 (49.7%) 148 (66.1%) 169 (70.1%) 61 (41.2%)
Depth of invasion T1-T2 66 (17.0%) 38 (28.8%) 28 (10.9%) 0.000 37 (24.5%) 29 (12.2%) 0.002 44 (26.7%) 22 (9.8%) 0.000 22 (9.1%) 44 (29.7%) 0.000
T3-T4 323 (83%) 94 (71.2%) 229 (89.1%) 114 (75.5%) 209 (87.8%) 121 (73.3%) 202 (90.2%) 219 (90.9%) 104 (70.3%)
Lymph node N0 72 (18.5%) 41 (31.1%) 31 (12.1%) 0.000 42 (27.8%) 30 (12.6%) 0.000 43 (26.1%) 29 (12.9%) 0.000 27 (11.2%) 45 (30.4%) 0.000
N1-N3 317 (81.5%) 91 (68.9%) 226 (87.9%) 109 (72.2%) 208 (87.4%) 122 (73.9%) 195 (87.1%) 214 (88.8%) 103 (69.6%)
Distant metastasis M0 235 (60.4%) 106 (80.3%) 129 (50.2%) 0.000 116 (76.8%) 119 (50.0%) 0.000 116 (70.3%) 119 (53.1%) 0.001 119 (49.4%) 116 (78.4%) 0.000
M1 154 (39.6%) 26 (19.7%) 128 (49.8%) 35 (23.2%) 119 (50.0%) 49 (29.7%) 105 (46.9%) 122 (50.6%) 32 (21.6%)
CEA (ng/ml) ≤5 243 (62.5%) 92 (69.7%) 151 (58.8%) 0.034 107 (70.9%) 136 (57.1%) 0.006 113 (68.5%) 130 (58.0%) 0.035 134 (55.6%) 109 (73.6%) 0.000
>5 146 (37.5%) 40 (30.3%) 106 (41.2%) 44 (29.1%) 102 (42.9%) 52 (31.5%) 94 (42.0%) 107 (44.4%) 39 (26.4%)
CA199 (U/ml) ≤37 278 (71.5%) 109 (82.6%) 169 (65.8%) 0.001 123 (81.5%) 155 (65.1%) 0.001 130 (78.8%) 148 (66.1%) 0.006 160 (66.4%) 118 (79.7%) 0.005
>37 111 (28.5%) 23 (17.4%) 88 (34.2%) 28 (18.5%) 83 (34.9%) 35 (21.2%) 76 (33.9%) 81 (33.6%) 30 (20.3%)
  1. NLR, neutrophil count to lymphocyte count; dNLR, neutrophil count to (white cell count – neutrophil count); PLR, platelet count to lymphocyte count; LMR, lymphocyte to monocyte ratio.
  2. *Difference between groups was tested by Chi-square test.
  3. aGrade 1 and 2 stand for high or middle differentiated tumor, grade 3 and 4 stand for poorly differentiated tumor.
  4. bTumor stage according to seventh edition of American Joint of Committee on Cancer.